EU/3/07/474

  • Email
  • Help

Orphan designation

On 14 September 2007, orphan designation (EU/3/07/474) was granted by the European Commission to CSL Behring GmbH, Germany, for alpha-1 proteinase inhibitor (inhalation use) for the treatment of cystic fibrosis.

What is cystic fibrosis?

Cystic fibrosis is an inherited disease. Cystic fibrosis is caused by abnormalities of a specific gene called CFTR. Cystic fibrosis appears only when the CFTR gene is abnormal on both chromosomes of the seventh pair (one inherited from the father, the other from the mother). In cystic fibrosis, defects of the CFTR gene decrease production of a protein that regulates outflow of water and ions (like chloride) from the cells that line the internal and external surfaces of the body, the so-called epithelial cells. This defective transport of water and salts results in the thickening of the secretions (mucus) in several organs, including the lungs and the pancreas. In turn, this leads to chronic and acute infections of the lungs, chronic inflammation (a body response to the injury caused to the tissue), and digestive difficulties. In the long term, these events can induce damage to the lung tissue and the disease becomes life-threatening.

What are the methods of treatment available?

At the time of submission of the application for the orphan drug designation, lung infection and inflammation in cystic fibrosis was treated mainly with antibiotics. These can be taken in a number of ways such as through the mouth, through a vein or they can be inhaled as a fine mist of particles. Associated treatments included daily exercise and physical therapies and several other types of medications such as pancreatic enzymes and food supplements. Bronchodilators are medications that can enlarge the airways. Mucolytics help to make the secretions thinner. Other medications were also used to fight the inflammation. Alpha-1 proteinase inhibitor (inhalation use) might be of potential significant benefit for the treatment of cystic fibrosis because it can act in a different way than other available medicines. This assumption will have to be confirmed at the time of marketing authorisation. This will be necessary to maintain orphan status.

What is the estimated number of patients affected by the condition*?

According to the information provided by the sponsor, cystic fibrosis was considered to affect about 65,000 persons in the European Union.

*Disclaimer: For the purpose of the designation, the number of patients affected by the condition is estimated and assessed based on data from the European Union (EU 27), Norway, Iceland and Lichtenstein. This represents a population of 498,000,000 (Eurostat 2006). This estimate is based on available information and calculations presented by the sponsor at the time of the application.

How is this medicinal product expected to act?

Alpha-1 proteinase inhibitor (also known as alpha-1 antitrypsin) is derived from the blood of human donors. This protein has the role of inactivating some harmful substances produced by the body itself, called neutrophil elastases, which are usually involved in the inflammation. In cystic fibrosis, due to the chronic inflammation, there is an excess of these elastases in the lung, contributing to the damage of the lung tissue. By local administration of additional alpha-1 proteinase inhibitor (via inhalation) it is expected that the accumulation of this harmful elastases wil be reduced, thereby slowing down the progression of the lung disease.

What is the stage of development of this medicinal product?

The effects of alpha-1 proteinase inhibitor (inhalation use) were evaluated in experimental models. At the time of submission of the application for orphan designation, no clinical trials in patients with cystic fibrosis had been initiated.

Alpha-1 proteinase inhibitor (inhalation use) was not authorised anywhere in the world for treatment of cystic fibrosis, or designated as orphan medicinal product elsewhere for this condition, at the time of submission.

According to Regulation (EC) No 141/2000 of 16 December 1999, the Committee for Orphan Medicinal Products (COMP) adopted on 25 July 2007 a positive opinion recommending the grant of the above-mentioned designation.

Opinions on orphan medicinal products designations are based on the following cumulative criteria:
  • the seriousness of the condition, 
  • the existence or not of alternative methods of diagnosis, prevention or treatment and 
  • either the rarity of the condition (considered to affect not more than five in ten thousand persons in the Community) or the insufficient return of development investments. 

Designated orphan medicinal products are still investigational products which were considered for designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of the quality, safety and efficacy will be necessary before this product can be granted a marketing authorisation.

Key facts

Product details for <p>Alpha1-proteinase inhibitor (inhalation use)</p>
Active substanceAlpha1-proteinase inhibitor (inhalation use)
Medicine Name
Disease/conditionTreatment of cystic fibrosis
Date of decision14/09/2007
OutcomePositive
Orphan decision numberEU/3/07/474

Review of designation

Sponsor’s contact details:

CSL Behring GmbH
Emil-von-Behring-Str. 76
35041 Marburg
Germany

Contact point:
Dr Othmar Zenker
Head Clinical R&D Europe
P.O. Box 1230
35002 Marburg
Germany
Telephone: + 49 6421 39 4728
Telefax: + 49 6421 39 2870
E-mail: othmar.zenker@cslbehring.com

Patients’ associations contact points:

CF : Cystic Fibrosis Association of Ireland
24 Lower Rathmines Road
Dublin 6
Dublin
Ireland
Telephone: +353 1 49 62 433
Telefax: +353 1 49 62 201
E-mail: info@cfireland.ie

Mukoviszidose e.V.
Deutsche Gesellschaft zur Bekämpfung der Mukoviszdose, gemeinnütziger Verein
Bendenweg 101
53121 Bonn
Germany
Telephone: +49 22 89 87 800
Telefax: +49 22 89 87 80 77
E-mail: info@mukoviszidose-ev.de

Vaincre la Mucoviscidose
181, rue de Tolbiac
75013 Paris
France
Telephone : +33 1 40 78 91 91
Telefax : +33 1 45 80 86 44
E-mail : info@vaincrelamuco.org